|
Patent landscape, scope, and claims: |
United States Patent 6,140,321 (Donepezil HCl Polymorph III): Claim Scope, Patent Landscape, and Generic Risk
US Patent 6,140,321 is a polymorph-centric estate on donepezil hydrochloride, anchored on a specific crystalline form (“Polymorph (III)”) defined by quantitative powder X-ray diffraction (PXRD) peak positions/intensities and KBr-FTIR absorption bands. The patent also claims multiple synthesis routes to that polymorph, plus downstream medical-use and composition claims tied to the same defined solid form. In practical enforcement, the estate’s value is limited by the requirement to match the claimed polymorph (III) identity data; design-around is most feasible via alternative salts, different solid forms, amorphous forms, or different polymorphs (I/II/other) that do not meet the recited PXRD/IR fingerprints.
What does US 6,140,321 claim for donepezil hydrochloride polymorph (III)?
Core claim subject matter
- Claim 1: donepezil hydrochloride in the form of polymorph (III) defined by:
- PXRD peaks specified by 2θ values with relative intensities (I/I₀), and
- IR absorption bands in KBr specified by wave numbers (cm⁻¹).
- Claim set covers:
- Solid form (product-by-structure via analytical fingerprints),
- Manufacturing processes to produce that polymorph,
- Method-of-treatment claims for acetylcholinesterase inhibition for senile dementia including Alzheimer’s type,
- Therapeutic composition claims including pharmacologically acceptable carriers.
Interpretation for infringement/validity
- Claim 1 is product-by-specification. In litigation, claim scope usually turns on whether accused material satisfies the exact “fingerprint” constraints:
- PXRD: peak list (2θ) and intensity thresholds are part of the definition.
- IR: the listed KBr bands must be present at the recited wavenumbers (typically read as requiring band matches within typical measurement tolerances).
- The dependent claims (2-7) narrow to particular crystallization/anti-solvent and acid-addition conditions that drive formation of polymorph (III).
- The method-of-use claims (8-10) are only as strong as the ability to prove the administered API is the claimed polymorph (III) form.
- Composition claim (11) similarly depends on inclusion of the polymorph (III) API.
What exact PXRD fingerprint defines Polymorph (III) in claim 1?
Claim 1 recites PXRD peaks for Polymorph (III):
| Feature type |
Values as recited in claim 1 |
| PXRD (2θ, degrees) |
6.56, 9.94, 13.00, 15.00, 15.26, 15.74, 16.48, 17.42, 18.10, 18.50, 19.50, 20.10, 20.94, 21.66, 22.32, 22.92, 23.92, 24.68, 26.00, 27.20, 28.02, 28.22, 28.60 |
| Relative intensity (I/I₀) |
30, 8, 17, 47, 14, 6, 35, 4, 21, 56, 17, 32, 21, 100, 25, 17, 19, 17, 44, 23, 29, 40, 13 |
What exact KBr-IR bands define Polymorph (III) in claim 1?
Claim 1 recites KBr IR absorption bands (cm⁻¹):
559, 641, 648, 702, 749, 765, 786, 807, 851, 872, 927, 949, 966, 975, 982, 1007, 1034, 1071, 1080, 1111, 1119, 1131, 1177, 1190, 1205, 1217, 1230, 1250, 1265, 1292, 1313, 1367, 1389, 1420, 1438, 1453, 1461, 1470, 1500, 1589, 1605, 1697, 2407, 2419, 2461, 2624, 2641, 2651, 2667, 2837, 2848, 2924, 2954, 2961, 2993, 3007, 3377, 3433.
How narrow are the polymorph definitions vs. broader “donepezil HCl” claims?
The patent is not a broad donepezil hydrochloride claim. It is a solid-state form claim using analytical identity data. This makes the estate:
- Strong against direct copying of the same polymorph, and
- Weaker against any applicant able to demonstrate a different polymorphic form or a material that does not satisfy the fingerprint constraints.
Do claims 2-7 cover the specific crystallization routes to polymorph (III)?
Claim 2: ethanol dissolution + diethyl ether addition.
Claim 3: methylene chloride dissolution + n-hexane addition.
Claim 4: acetone dissolution + HCl or hydrogen chloride addition.
Claim 5: ethyl acetate dissolution + HCl or hydrogen chloride addition.
Claim 6: ethanol dissolution + HCl/HCl addition + anti-solvent selected from diethyl ether, isopropyl ether, n-hexane.
Claim 7: Claim 6 limited to isopropyl ether anti-solvent and crystallization/filtration timing: filtrated in one or more hours after they have precipitated.
Scope mechanics
These process claims are tied to the outcome: they are processes “for producing polymorph (III)” as defined in claim 1. In dispute, the patentee typically must prove:
- the process is carried out as claimed, and
- the resulting product is polymorph (III) by the claimed PXRD/IR fingerprint.
For generic manufacturers, process modification only matters if it changes solid-state outcome (i.e., produces a different polymorph or amorphous form that fails the fingerprint).
Which method-of-use claims are tied to acetylcholinesterase inhibition and senile dementia?
Claim 8: treating “a disease accompanied by acetylcholinesterase activity” by administering pharmacologically effective amount of donepezil HCl in polymorph (III) form, for inhibiting acetylcholinesterase activity.
Claim 9: disease is senile dementia.
Claim 10: senile dementia of the Alzheimer type.
Scope mechanics
- These are medical use claims but still depend on the API being the polymorph (III) form.
- If an accused product uses a different polymorph or solid-state form, the medical-use claim can be harder to establish, because the administration element becomes a solid-form element.
Does US 6,140,321 claim formulations or only the API solid form?
Claim 11: therapeutic composition comprising a pharmacologically effective amount of donepezil hydrochloride in polymorph (III) form plus a pharmacologically acceptable carrier.
What this implies
- The claim does not list specific excipients or dosage forms (tablet, capsule, etc.) in the text provided, so the “carrier” is likely broad.
- However, enforcement still requires showing the composition contains donepezil hydrochloride specifically in polymorph (III) form.
How do polymorph (I) and polymorph (II) recited in the patent affect claim strength and design-around?
The claim text you provided includes additional polymorph fingerprints for polymorph (I) and polymorph (II) inside the same claim’s dependency logic (claim 12 referencing heating polymorph (I) or (II) to produce polymorph (III)).
Polymorph (I) and polymorph (II) are defined via distinct PXRD and KBr-IR lists, demonstrating that the patentee is not claiming “any crystalline donepezil HCl.” It claims a specific crystallographic/solid-state form.
Design-around direction
- If a manufacturer can produce polymorph (I), polymorph (II), or another form that does not match polymorph (III)’s PXRD/IR fingerprint, it can avoid claim 1.
- Even if donepezil HCl is present, the infringement hinge is whether it matches the specific analytical definition of polymorph (III).
What patent landscape does US 6,140,321 sit in for donepezil hydrochloride polymorphs?
How this specific patent typically fits in the broader estate
In donepezil, the commercial core is well established (immediate-release tablets/capsules). Polymorph patents like US 6,140,321 usually sit in the “secondary patenting” layer:
- solid form patents (polymorph/salt/hydrate),
- process patents for producing a solid form,
- and downstream use or composition claims tied to that form.
Claim-driven landscape implication
- A polymorph estate is generally narrower than:
- primary compound patents, or
- broad dosing/use patents detached from a specific solid form.
- Its practical leverage is tied to:
- manufacturing control (does your process yield the same polymorph?),
- solid-state characterization (can you prove identity by PXRD/IR?), and
- regulatory and litigation evidence (what solid form is used in the ANDA or drug master record).
When does US 6,140,321 lose enforceability under US patent term rules?
No complete answer is possible from the information provided. Patent expiration depends on:
- filing date,
- earliest priority date,
- and any term adjustments or extensions.
Without those bibliographic facts for US 6,140,321, the exclusivity timeline cannot be calculated precisely.
What Orange Book status would matter for generic entry risk?
No complete answer is possible from the information provided. Orange Book status requires:
- the listed application(s),
- listed patents per strength/form,
- and whether US 6,140,321 is listed for the relevant NDA/strength/dosage form.
Paragraph IV and settlement landscape for polymorph patents: what to expect?
No complete answer is possible from the information provided. To map Paragraph IV challenges and settlements, you need the Orange Book listing and litigation history tied to that specific listed patent.
How strong is the patent estate for US 6,140,321 based on claim architecture?
Strength drivers
- Objective identity definition: PXRD and KBr-IR lists anchor claim scope.
- Outcome-coupled process claims: process claims are tied to producing the polymorph defined in claim 1.
- Downstream dependence: method-of-use and composition claims require the polymorph (III) form.
Risk/weakness drivers for enforcement
- Analytical proof burden: the patentee must show the accused material matches the specified PXRD/IR fingerprints.
- Tolerance and measurement disputes: PXRD peak presence and intensity can vary with instrument, sample prep, and conditions. A defendant can try to show non-conformance.
- Manufacturing flexibility: generics can often alter crystallization conditions and polymorphic outcome without changing the pharmacological compound.
What generic entry risks exist for a donepezil polymorph (III) patent like this?
Risk is highest when:
- the generic’s manufacturing process is similar to the claimed crystallization conditions and yields polymorph (III),
- the generic cannot verify alternative solid-state form equivalence,
- and the submitted characterization evidence supports polymorph (III) identity.
Risk is lower when:
- the generic uses a different polymorph (I or II) or another form,
- it uses a solid-state control strategy that yields a different powder fingerprint,
- or it can demonstrate that the API in its final product does not match polymorph (III) by PXRD/IR.
Key Takeaways
- US 6,140,321 is a polymorph-specific donepezil hydrochloride patent, with claim 1 defining polymorph (III) via PXRD peak positions and relative intensities plus KBr-IR absorption bands.
- The estate includes process claims (ethanol/ether; methylene chloride/n-hexane; acetone with HCl; ethyl acetate with HCl; and ethanol with HCl plus selected anti-solvents) that are limited by the requirement to produce polymorph (III).
- Medical-use and composition claims depend on administration of the same polymorph (III) form, creating both leverage and an evidence-heavy infringement burden.
- Landscape and timing (Orange Book status, Paragraph IV, expiration date, settlements) cannot be determined from the claim text alone; those require bibliographic and Orange Book listing data.
FAQs
1) What is the main claim limitation in US 6,140,321 for polymorph (III) infringement?
The API must match the polymorph (III) analytical fingerprint defined in claim 1 (specific PXRD 2θ/intensity list and specific KBr-IR wave numbers).
2) Do claims 2-7 protect crystallization conditions regardless of the resulting solid form?
No. They are processes “for producing polymorph (III),” so the resulting solid form must match the claim 1 polymorph definition.
3) Can a product avoid infringement by using polymorph (I) or (II) instead?
If polymorph (I) or (II) does not satisfy the polymorph (III) PXRD/IR constraints, it can fall outside claim 1 and the dependent claims that require polymorph (III).
4) Are the method-of-use claims broad enough to cover any donepezil HCl?
No. Claims 8-10 require administering donepezil hydrochloride in polymorph (III) form.
5) What downstream patent exposure does a formulation have under claim 11?
A formulation claim still depends on containing donepezil hydrochloride in polymorph (III) plus a pharmacologically acceptable carrier.
References
- US Patent 6,140,321. “Donepezil hydrochloride polymorph (III) and processes, therapeutic uses, and compositions.” (Claims as provided in prompt).
More… ↓
⤷ Start Trial
|
